Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 8/20 | 0.51 |
| ▸ | SELE | P16581 | 8/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.44 |
| ▸ | CDC7 | O00311 | 2/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | GABRE | P78334 | 1/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430905 | 1.00 | ICAM1 (0.51) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL7255085 | 0.84 | ICAM1 (0.52) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL29831616 | 0.84 | ICAM1 (0.56) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL5550652 | 0.84 | ICAM1 (0.56) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL27192049 | 0.83 | ICAM1 (0.54) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL31509890 | 0.83 | ICAM1 (0.54) | ICAM1SELEPTPN2VCAM1CDC7 | |
| SCHEMBL20278452 | 0.81 | CDK8 (0.55) | ICAM1SELEVCAM1CDC7CDK8 | |
| SCHEMBL20906131 | 0.80 | PTPN2 (0.49) | ICAM1SELEPTPN2KDM4E | |
| SCHEMBL18105584 | 0.79 | ICAM1 (0.53) | ICAM1SELEVCAM1CDC7CDK8 | |
| SCHEMBL17080891 | 0.79 | SLC9A1 (0.53) | ICAM1SELEPTPN2KDM4EGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878551-A | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118878551-B | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2026-04-28 | — | — | CN | disclosed |
| CN-118878551-B | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2026-04-28 | — | — | CN | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-118878551-A | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-118878551-A | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-118878551-A | Preparation method of 4-bromothieno [2,3-c ] pyridine-2-carboxylic acid ethyl ester | 安徽大学 | 2024-11-01 | — | — | CN | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3275867-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-08 | — | — | US | disclosed |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-06-08 | — | — | US | disclosed |
| EP-3115361-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-11 | — | — | EP | disclosed |
| WO-2016150255-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海璎黎药业有限公司 | 2016-09-29 | — | — | WO | disclosed |
| WO-2015131856-A1 | HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF | 中国科学院上海药物研究所 | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ICAM1 2883/4885SELE 3804/4885PTPN2 878/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | ICAM1 2883/4885SELE 3804/4885PTPN2 878/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | ICAM1 2883/4885SELE 3804/4885PTPN2 878/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ICAM1 2883/4885SELE 3804/4885PTPN2 878/4885 |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | ICAM1 3383/4885SELE 4482/4885PTPN2 4644/4885 |
| US-20170158680-A1 | HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | CYP11B2, CYP11B1, ADCYAP1R1 | ICAM1 4793/4885SELE 3681/4885PTPN2 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.